Literature DB >> 12749717

Case-control study of lung cancer during 1994-1997 in the birth cohort in Tasmania, Australia, with an excess of female cases during 1983-1992.

Leigh Blizzard1, Terence Dwyer.   

Abstract

OBJECTIVE: In Tasmania, Australia, lung cancer incidence for 25-44-year-old women has reached that of 25-44-year-old men despite less smoking by the women. We investigated whether this could be due to greater female-than-male relative risk for smoking.
METHODS: This was a case-control study of lung cancer in the 1939-1964 birth cohort. In person (n = 100) or by proxy, 158 of the 160 cases arising during 1994-1997 were interviewed. Controls were a representative sample of the cohort (response 82.8%). Detailed measurements of tobacco smoking were made by questionnaire, and using the results of 17 machine tests of cigarette "tar" yields.
RESULTS: The male smokers had greater accumulated exposure to smoking and, in reversal of the previously reported excess of female cases in this cohort, most (99/160) of the 1994-1997 cases were men. Nevertheless, the proportions attributable to smoking were similar: 0.86 (0.76-0.97) of male cases, and 0.87 (0.74-0.99) of female cases. Calculated relative to male never-smokers, the estimated relative risks were similar for male and female smokers, particularly with exposure measured by cumulative tar yield of all cigarettes smoked.
CONCLUSIONS: We found no compelling evidence of greater susceptibility to lung cancer for female smokers.

Entities:  

Mesh:

Year:  2003        PMID: 12749717     DOI: 10.1023/a:1023001932619

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  1 in total

1.  Case-control study of cumulative cigarette tar exposure and lung and upper aerodigestive tract cancers.

Authors:  Travis J Meyers; Shen-Chih Chang; Po-Yin Chang; Hal Morgenstern; Donald P Tashkin; Jian-Yu Rao; Wendy Cozen; Thomas M Mack; Zuo-Feng Zhang
Journal:  Int J Cancer       Date:  2017-02-22       Impact factor: 7.396

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.